Dexmedetomidine Clinical Trial
Official title:
A Comparative Study of Propofol-Fentanyl-Dexmedetomidine and Propofol-Fentanyl-Sevoflurane Anesthesia for Major Spine Surgery Under Somato Sensory- and Motor- Evoked Potential Monitoring
The objective of this study is to evaluate the effect of adding dexmedetomidine on evoked potentials in adult patients undergoing spinal surgery under intravenous anesthesia
Status | Recruiting |
Enrollment | 78 |
Est. completion date | September 1, 2024 |
Est. primary completion date | September 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 45 Years |
Eligibility | Inclusion Criteria: - Age from 21-45 years. - Both sexes. - American Society of Anesthesiology (ASA) physical status I and II. - Undergoing major spine surgery Exclusion Criteria: - Refusal of procedure or participation in the study by patients. - Patients with known history of allergy to one of study drugs - Patients with nerve conduction pathway injury. - Severe circulatory or respiratory disease. - Cognitive or psychiatric illness that leads to inability to cooperate, speak or provide informed consent - Patients with history of Myasthenia gravis, epilepsy , history of pacemaker implantation . - Patients who need to be awakened during the procedure. |
Country | Name | City | State |
---|---|---|---|
Egypt | Ain Shams University | Cairo |
Lead Sponsor | Collaborator |
---|---|
Ain Shams University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The amplitude score of Somato sensory evoked potential | The amplitude score of the waveforms will be measured. More than 50% decrease in the amplitude and more than 10% prolongation of the latency of Compound muscle action potential ( CMAP) from the baseline values will be defined as significant | 6 hours postoperatively | |
Secondary | The latency of Somato sensory evoked potential | The latency of the waveforms will be measured. More than 50% decrease in the amplitude and more than 10% prolongation of the latency of Compound muscle action potential (CMAP) from the baseline values will be defined as significant | 6 hours postoperatively | |
Secondary | The latency of motor evoked potential | The latency of the waveforms will be measured. More than 50% decrease in the amplitude and more than 10% prolongation of the latency of Compound muscle action potential (CMAP) from the baseline values will be defined as significant | 6 hours postoperatively | |
Secondary | The amplitude score of motor evoked potential | The amplitude of the waveforms will be measured. More than 50% decrease in the amplitude and more than 10% prolongation of the latency of Compound muscle action potential (CMAP) from the baseline values will be defined as significant | 6 hours postoperatively | |
Secondary | Intraoperative fentanyl consumption | Fentanyl (1 ug/kg) will be used to induce anesthesia. | Intraoperatively | |
Secondary | Intraoperative propofol consumption | Propofol (2mg/kg) will be used to induce anesthesia | Intraoperatively | |
Secondary | Intraoperative dexmedetomidine consumption | Dexmedetomidine (0.5ug/kg) loading dose infused over 10 mins followed by a constant infusion rate of (0.2ug/kg/hr) | Intraoperatively | |
Secondary | Intraoperative sevoflurane consumption | the anesthesia will be maintained with inhalational anesthesia of 50% oxygen , 50% air plus sevoflurane concentration adjusted to keep BIS between 40 & 50 | Intraoperatively | |
Secondary | Changes in heart rate | Heart rate will be assessed immediately before the operation and every 10 minutes in the first 30 minutes of the operation then every 15 minutes till the end of the operation. | Till the end of operation | |
Secondary | Changes in mean arterial pressure | Mean arterial pressure will be assessed immediately before the operation and every 10 minutes in the first 30 minutes of the operation then every 15 minutes till the end of operation | Till the end of operation | |
Secondary | Quality of surgical field | Quality of surgical field will be evaluated every 15 minutes using the surgical field rating (SFR) scale of six points : 5 - massive uncontrollable bleeding, 4 - heavy but controllable bleeding that significantly interfered with dissection, 3 - moderate bleeding that moderately compromised surgical dissection, 2 - moderate bleeding - a nuisance but without interference with accurate dissection, 1 - bleeding, so mild it was not even a surgical nuisance, 0 - no bleeding and virtually bloodless field. Surgical field was graded as good, fair, and poor as: good - SFR scale 0 or 1, fair - SFR scale 2or 3, poor - SFR scale 4 or 5). | Till the end of operation | |
Secondary | Intraoperative bleeding | Intraoperative bleeding will be measured by collecting blood in a marked container of 2500 ml capacity and the blood soaked by gauze pieces [4×4 soaked gauze piece (15 ml blood), completely soaked abdominal towel (150 ml blood)] | Intraoperatively |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04577430 -
Effects of Dexmedetomidine on Cardiac Electrophysiology in Patients Under General Anesthesia During Perioperative Period
|
N/A | |
Completed |
NCT03220880 -
Intranasal Dexmedetomidine Sedation in Children for Non-painful Procedures
|
||
Completed |
NCT05291364 -
Dexmedetomidine in Splanchnic Nerve Neurolysis
|
N/A | |
Recruiting |
NCT05249153 -
Dexmedetomidine and Sufentanil Effect in PCA on Pediatric Patients Undergoing Scoliosis Surgery
|
N/A | |
Completed |
NCT01688648 -
Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
|
N/A | |
Completed |
NCT05103735 -
Propofol-remifentanyl Versus Dexmedetomidine in Awake Craniotomy: Impact on Electroclinical Seizure Activity
|
||
Recruiting |
NCT06030804 -
Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery
|
N/A | |
Terminated |
NCT03253224 -
Magnesium and Postoperative Pain
|
Phase 4 | |
Recruiting |
NCT05525819 -
Intrathecal Versus Intravenous Dexmedetomidine in Prostate Transurethral Resection
|
N/A | |
Completed |
NCT04665453 -
Dexmedetomidine and Melatonin for Sleep Induction for EEG in Children
|
N/A | |
Completed |
NCT06018948 -
Effect of Two Different Doses of Dexmedetomidine Infusion in Morbidly Obese Patients
|
Phase 4 | |
Completed |
NCT03658421 -
Dexmedetomidine as Adjuvant for FNB in TKA
|
N/A | |
Completed |
NCT03775655 -
Low Dose Hyperbaric Bupivacaine and Dexmedetomidine as an Adjuvant, Caesarean Section
|
Phase 2/Phase 3 | |
Completed |
NCT03234660 -
Dexmedetomidine and Neuroprotection in Children Undergoing General Anesthesia
|
N/A | |
Completed |
NCT06020781 -
Efficacy and Safety of Dexmedetomidine to Bupivacaine in Supraclavicular Brachial Plexus Block
|
N/A | |
Recruiting |
NCT06207331 -
Effects of Atomized Dexmedetomidine on Lung Function in Patients With Chronic Obstructive Pulmonary Disease
|
N/A | |
Active, not recruiting |
NCT03629262 -
Dexmedetomidine Supplemented Intravenous Analgesia in Elderly After Orthopedic Surgery
|
Phase 4 | |
Completed |
NCT06098209 -
Dexmedetomidine and Propofol in Mechanically Ventilated Patients by Using Salivary Alpha-amylase as a Stress Marker
|
N/A | |
Not yet recruiting |
NCT06062550 -
Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery
|
Phase 4 | |
Completed |
NCT02211118 -
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
|
Phase 4 |